<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="66467">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02240589</url>
  </required_header>
  <id_info>
    <org_study_id>A70-4-0791023</org_study_id>
    <nct_id>NCT02240589</nct_id>
  </id_info>
  <brief_title>Memantine for Neuroprotection and Cognitive Enhancement Following Traumatic Brain Injury</brief_title>
  <official_title>Memantine for Neuroprotection and Cognitive Enhancement Following Traumatic Brain Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if memantine can improve cognitive and
      neuropsychiatric outcomes after severe traumatic brain injury.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot/feasibility study of memantine in severe traumatic brain injury (TBI)
      persons, employing a randomized, double-blind, placebo-controlled, design. Outcome
      evaluations will occur after 24 weeks of treatment (on medication) and 4 weeks after
      treatment discontinuation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>California Verbal Learning Test - Second Edition (CVLT-II) - free delayed recall</measure>
    <time_frame>Week 24</time_frame>
    <description>Neuropsychological test used to assess an individual's verbal memory abilities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CVLT-II Trials 1-5 Total</measure>
    <time_frame>Week 24</time_frame>
    <description>Neuropsychological test used to assess an individual's verbal memory abilities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CVLT-II % retention</measure>
    <time_frame>Week 24</time_frame>
    <description>Neuropsychological test used to assess an individual's verbal memory abilities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Visuospatial Memory Test - Revised (BVMT-R) Delayed Recall</measure>
    <time_frame>Week 24</time_frame>
    <description>Neuropsychological test to assess a person's visuospatial memory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BVMT-R Trials 1-3</measure>
    <time_frame>Week 24</time_frame>
    <description>Neuropsychological test to assess a person's visuospatial memory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trail Making Part B</measure>
    <time_frame>Week 24</time_frame>
    <description>Neuropsychological test of visual attention and executive functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroop interference</measure>
    <time_frame>Week 24</time_frame>
    <description>Neuropsychological test to assess a person's selective attention, cognitive flexibility and processing speed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavior Rating Inventory of Executive Function (BRIEF) Inhibit</measure>
    <time_frame>Week 24</time_frame>
    <description>Neuropsychological test to assess a person's ability to control impulses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Traumatic Brain Injury Quality of Life Anger (TBI QOL Anger)</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Memantine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 weeks of memantine with accelerated titration, beginning within 48 hours of injury.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>24 weeks of placebo matched to memantine formulation, beginning within 48 hours of injury.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine</intervention_name>
    <description>Day 1 to 3: 10 mg bid memantine. Day 3 to 21: 20 mg bid memantine. Day 21 to 168: 10 mg bid memantine.</description>
    <arm_group_label>Memantine</arm_group_label>
    <other_name>Namenda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Day 1 to 3: 10 mg bid placebo. Day 3 to 21: 20 mg bid placebo. Day 21 to 168: 10 mg bid placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-65 years old of age at time of enrollment

          -  Severe traumatic brain injury (TBI)

          -  Feeding access (e.g., orogastric (OG), nasogastric (NG), or percutaneous endoscopic
             gastrostomy (PEG) tube) permitting delivery of memantine or placebo

          -  Availability of legally-authorized representative (LAR) to provide consent and
             participate in some study activities (e.g., monitoring for side effects, providing
             information about the patient)

        Exclusion Criteria:

          -  Pre-existing history of serious neurological disorder

          -  Pre-existing history of serious psychiatric disorder (e.g., schizophrenia)

          -  Anticipated poor prognosis, based on the presence of bilaterally fixed and dilated
             pupils, severe hemodynamic instability, severe elevations in intracranial pressure
             refractory to interventions, or other factors leading to a determination of a
             probable non-survivable injury

          -  Primarily penetrating mechanism of injury (e.g., gunshot wound to the head)

          -  Isolated epidural hematoma with anticipated good prognosis

          -  Low probability of participant being compliant or being able to finish study
             procedures (e.g., present for outcome rating) in the judgment of the investigator

          -  Not English speaking (due to inability to complete outcome measure)

          -  Medical contraindications to memantine: Severe hepatic impairment (defined as albumin
             &gt; 15gm/dL, Alk Phos &gt; 375 U/L, ALT &gt; 150 U/L, AST &gt; 120 U/L or bilirubin &gt; 3mg/dL).
             Moderate-to-Severe renal impairment (defined as creatinine clearance &lt; 60)

          -  Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Flora Hammond, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Health Facilities</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 5, 2016</lastchanged_date>
  <firstreceived_date>September 11, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Flora Hammond</investigator_full_name>
    <investigator_title>Covalt Professor &amp; Chair</investigator_title>
  </responsible_party>
  <keyword>Traumatic Brain Injury</keyword>
  <keyword>Memantine</keyword>
  <keyword>Memory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
